Canada markets open in 1 hour 36 minutes

MERCK Kommanditgesellschaft auf Aktien (MRK.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
192.50-0.60 (-0.31%)
As of 1:39PM CEST. Market open.
Full screen
Previous Close193.10
Open194.90
Bid192.60 x 6700
Ask192.65 x 11200
Day's Range191.75 - 196.45
52 Week Range121.25 - 207.90
Volume99,163
Avg. Volume318,237
Market Cap83.695B
Beta (5Y Monthly)0.49
PE Ratio (TTM)30.67
EPS (TTM)6.28
Earnings DateNov. 11, 2021
Forward Dividend & Yield1.40 (0.73%)
Ex-Dividend DateApr. 26, 2021
1y Target Est199.50
  • Zacks

    Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255

    Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

  • Reuters

    Supply fears lead EU vaccine industry to seek home comforts

    FRANKFURT (Reuters) -European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic. Germany's Merck KGaA, whose Life Science unit is one of the world's largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders. U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.

  • Reuters

    Merck KGaA says lab supplies business can grow by up to 10% per year

    Germany's Merck KGaA on Thursday issued a more ambitious medium-term growth forecast for its Life Science unit, as manufacturers of COVID-19 vaccines and treatments snap up its materials and gear. Life Science division revenues are now expected to grow 7% to 10% per year until 2025, excluding the effect of currencies and acquisitions, significantly above market growth and higher than a previous goal of 6% to 9%, the diversified company said. "Life Science will sharpen its focus on the Asia-Pacific region, especially China, as well as on innovations and digital solutions in all businesses," the company said in a statement on its capital markets day on Thursday.